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The C-C chemokine receptor type 5 (CCR5) is a
receptor expressed by T cells and macrophages
that serves as a coreceptor for macrophage-tropic
HIV-1. Loss of CCR5 is associated with resistance
to HIV-1. Here, we combine the live-cell-based
SELEX with high-throughput sequencing technology
to generate CCR5 RNA aptamers capable of specif-
ically targeting HIV-1 susceptible cells (as small
interfering RNA [siRNA] delivery agent) and inhibiting
HIV-1 infectivity (as antiviral agent) via block of the
CCR5 required for HIV-1 to enter cells. One of the
best candidates, G-3, efficiently bound and was
internalized into human CCR5-expressing cells. The
G-3 specifically neutralized R5 virus infection in pri-
mary peripheral blood mononuclear cells, and in vivo
generated human CD4+ T cells with a nanomolar
inhibitory concentration 50%. G-3 was also capable
of transferring functional siRNAs to CCR5-express-
ing cells. Collectively, the cell-specific, internalizing,
CCR5-targeted aptamers and aptamer-siRNA conju-
gates offer promise for overcoming some of the
current challenges of drug resistance in HIV-1 by
providing cell-type- or tissue-specific delivery of
various therapeutic moieties.
INTRODUCTION
Nucleic acid-based therapeutics are quickly emerging as a
strong alternative or co-therapy to the chemical antiviral agents
currently used to treat HIV-1/AIDS. The combinatorial use of
various antiviral nucleic acids could bemore efficacious in block-
ing viral replication and preventing the emergence of resistant
HIV-1 variants (Joshi et al., 2003; Scherer et al., 2007). In addi-
tion, highly specific nucleic acid-based aptamers and aptamer-
functionalized agents have been used extensively for targetedChemistry & Biology 22, 3diseases therapy (Li et al., 2013; Nimjee et al., 2005; Sundaram
et al., 2013; Thiel and Giangrande, 2009; Zhang et al., 2004).
These aptamers often have favorable characteristics, such as
small size, high stability (dehydrated form), lack of immunoge-
nicity, facile chemical synthesis, adaptable modification, and
cell-free evolution. To date, many nucleic acid aptamers have
been shown to be specific to various regions of the HIV-1
genome and to HIV-1-dependent proteins, including HIV-1
reverse transcriptase (RT), integrase (IN), nucleocapsid (NC),
group-specific antigen (Gag), transactivation response (TAR)
element, regulator of expression of virion proteins (Rev), transac-
tivator of transcription (Tat), envelope glycoprotein 120 (gp120),
and cluster of differentiation 4 (CD4) protein (Shum et al., 2013).
These aptamers have been raised through the purified protein-
based SELEX (systematic evolution of ligand exponential enrich-
ment) method and shown to effectively suppress viral replication
(Held et al., 2006; Shum et al., 2013; Zhang et al., 2004). Impor-
tantly, a number of cell-specific aptamers targeting cell surface
proteins have been adapted as promising delivery vehicles for
the targeted cell-type-specific delivery of small interfering RNA
(siRNA) (Mallikaratchy et al., 2009; Zhou and Rossi, 2011b).
Moreover, the combined use of siRNAs and aptamers could
effectively block viral replication and prevent the emergence of
resistant variants (Zhou and Rossi, 2012).
In our previous efforts, anti-HIV gp120 aptamers were com-
bined with anti-HIV siRNAs to achieve a dual inhibitory drug
capable of delivering siRNAs selectively to HIV-infected cells as
well as inhibiting viral entry via blocking of the envelope interac-
tion with the CD4 (Neff et al., 2011; Zhou et al., 2013). Human
CCR5 (C-C chemokine receptor type 5), a protein expressed by
T cells and macrophages, is an important coreceptor for macro-
phage-tropic virus, including HIV-1 R5 isolates (Berger et al.,
1999; Pelchen-Matthews et al., 1999). Variations in CCR5 are
associatedwith resistanceor susceptibility toHIV-1.Asanessen-
tial factor for viral entry, CCR5 has represented an attractive
cellular target for the treatment of HIV-1 (Meanwell and Kadow,
2003; Ugolini et al., 1999). We therefore sought to develop
CCR5-directed RNA aptamers to target HIV-1-susceptible cells
and specifically regulate both gene silencing of HIV-1 and the
blockage of CCR5, which is required for HIV-1 to enter cells.79–390, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 379
Figure 1. Live-Cell-Based SELEX and Bioin-
formatics Analysis of HTS Data from Selec-
tion Rounds
(A) Schematic of the live-cell-based SELEX pro-
cedure for evolution of RNA aptamers. It consists
of four main steps: (1) counterselection by incu-
bating library with negative cells that do not ex-
press the target protein; (2) positive selection by
incubating recovered unbound sequences with
positive cells expressing the target protein; (3)
recovery of target-bound sequences; and finally
(4) reamplification of recovered species and
making a new RNA pool for the next selection
round. Individual aptamer sequences are identi-
fied through barcode-based Illumina deep
sequencing (HTS) and bioinformatics analysis.
ssDNA, single-stranded DNA.
(B) The progress of SELEX. Nine rounds of live-
cell-based SELEX were performed to enrich for
RNA aptamers. Cell-type-specific binding/inter-
nalization of ten RNA pools was evaluated by qRT-
PCR. Asterisks represent the significant molecular
enrichment at selection rounds 7, 8, and 9.
(C) The molecular enrichment at each round. The
molecular enrichment at each round was calcu-
lated by the formula (total reads of top 1000 se-
quences in round X/round 5).
(D) The frequency of each group at each selection
round. After alignment of the top 40 sequences,
six groups of aptamers were identified. The
percent frequency of each group at each selection
round was calculated by the formula (the reads of
each group/the useful reads at each round).
Error bars represent SD.By combining the live-cell-based SELEX strategy (Cerchia
et al., 2009b; Fang and Tan, 2009) (Figure 1A) with high-
throughput sequencing (HTS) and bioinformatics analysis, we
have successfully identified several 20-fluoropyrimidine modified
RNA aptamers directed to human CCR5. One of the best candi-
dates (G-3) efficiently bound to CCR5 and was internalized into
human CCR5-expressing Magi-U373-CCR5E cells, CEM-NKr-
CCR5 cells, and primary peripheral blood mononuclear cells
(PBMCs). The G-3 aptamer specifically neutralized R5-tropic
virus infection in primary PBMCs and in vivo generated human
CD4+ T cells with about 50–350 nM of inhibitory concentration
50% (IC50). Moreover, the G-3 aptamer was capable of deliv-
ering functional anti-HIV siRNAs to CCR5-expressing cells in a
receptor-targeted manner, thereby resulting in a dual inhibitory
effect on HIV-1 replication. Collectively, we describe the deriva-380 Chemistry & Biology 22, 379–390, March 19, 2015 ª2015 Elsevier Ltd All rights reservedtion and mechanistic characterization of
new CCR5 targeted aptamers, which
may prove useful in several applications,
including use as a novel antiviral therapy.
RESULTS
Live-Cell-Based SELEX of CCR5
Aptamers
RNA aptamers, 20-fluoropyrimidine modi-
fied, were selected using the live-cell-based SELEX strategy (Cerchia et al., 2005, 2009a; Thiel
et al., 2012a, 2012b) (Figure 1A). Cellular surface CCR5
expression in target U373-Magi-CCR5E cells was first verified
using flow cytometric analysis (Figure S1) and a counterselec-
tion step with U373-Magi cells (CCR5 negative). The detailed
selection conditions are summarized in Figure 1A and Table
S1. Nine selection rounds containing both positive and negative
selection were performed with cell-specific binding and inter-
nalization of the RNA pools monitored using quantitative RT-
PCR (qRT-PCR). A significant enrichment was observed
between the seventh (7-RNA pool) and the ninth round RNA
pool (9-RNA pool) (Figure 1B). No further increase could be
detected after the eighth selection round, suggesting that
maximal binding/internalization of the RNA pool may have
been reached.
Table 1. Bioinformatics Analysis of HTS Data from Selection Rounds
Round 5 Round 6 Round 7 Round 8 Round 9
Total reads 48,175,338 37,973,185 36,503,548 27,876,693 30,723,210
Useful reads 35,003,576 24,043,982 25,650,155 17,994,328 16,273,964
Total reads of top 1,000 unique sequences 1,553,154 8,877,699 18,721,730 15,831,299 15,473,124
Molecular enrichment (fold) 1.00 5.72 12.05 10.19 9.96
The total reads and useful reads were defined as follows: the most frequent 1,000 unique sequences were identified and listed for clarity; themolecular
enrichment at each round was calculated using the formula (total reads of top 1000 unique sequences at round X/round 5).Identification of CCR5 Aptamers Using HTS
By using barcode-based Illumina deep sequencing technology,
HTS was performed for the RNA pools from selection round 5
to 9, with approximately 30–50 million total reads obtained
from each sequenced round (Table 1). After removal of constant
region and sequencing adapter sequences, the raw reads were
filtered based on the length of RNA library random region
sequence, and the most frequent 1,000 unique sequences iden-
tified (Table 1; Figure S2A). A significant increase in the fre-
quencies of the top 1,000 unique sequences was observed
after the seventh round of selection, suggesting a decrease in
library sequence diversity and an increase in library sequence
enrichment at this step. Supporting this notion are the obser-
vations that after round 7, the molecular diversity was dramati-
cally converged, thereby suggesting some specific sequences
have been successfully enriched during the selection (Fig-
ure 1C). These observations are consistent with SELEX progress
(Figure 1B).
The distribution of each nucleotide (A, T, C, and G) at the 20-nt
random region within the RNA sequence of the top 1,000 candi-
dates from each roundwas identified (Figure S2B). The individual
sequences were classified into six major groups (groups 1–6)
based on the alignments of the top 1,000 unique aptamer se-
quences (Table 2). One representative sequence from each
group (G-1, G-2, G-3, G-4, G-5, and G-6) was listed for further
characterization because of their relative abundance within their
group. Theoretical secondary structureswere predicted by using
RNA folding algorithm Mfold (Figure S2C). Groups 2, 4, and 5
shared a conserved sequence, which comprises ten nucleotides
UUCGUCUG(U/G)G (Figure S2C). Furthermore, we calculated
the percent frequency to determine the evolution of each
sequence group from round 5 to 9 (Figure 1D). A progressive
evolution of all the groups was observed from round 5 to
round 7, in which the maximal selection convergence or bind-
ing/internalization of the RNA pool has been achieved (Tables 1
and 2; Figure 1B). Importantly, a significant increase of group 1
sequence observed at round 9 compromised a population of
other groups, implying that further selectionmay adversely affect
the enrichment of the candidate aptamers.
CCR5 RNA Aptamers Bind to Cell Surface CCR5 and Are
Internalized into CCR5-Expressing Cells
To evaluate the binding affinity and internalization potential of
these individual RNA aptamers, one representative sequence
from each group (G-1, G-2, G-3, G-4, G-5, and G-6) was synthe-
sized for further characterization. U373-Magi-CCR5E cells sta-
bly expressing the CCR5 protein and its parental U373-Magi
(CCR5 negative) control cells were used to test for binding andChemistry & Biology 22, 3internalization of the candidate aptamers. Cell-type-specific
binding and internalization was first detected by using qRT-
PCR. These RNA aptamers were able to selectively bind and
internalize into U373-Magi-CCR5E cells (Figure 2A). Next, these
RNA aptamers were labeled with Cy3 dye, and their binding and
cellular uptake were determined. Flow cytometric analysis re-
vealed that the aptamers specifically bound to the U373-Magi
CCR5E cells but did not bind to the control U373-Magi cells
(CCR5 negative) (Figure 2B; Figures S3A and S3B).
To determine the ability of the candidate aptamers to selec-
tively bind to different cells expressing human CCR5, the
aptamers were applied to the human T-lymphoblastoid cell line
(CEM-NKr-CCR5 cell) and primary PBMCs isolated from
different donors. The top candidate aptamer, G-3, was selected
for further analysis, as it was able to bind CCR5 in the various
CCR5-expressing cells. Moreover, this aptamer was refractory
to binding the non-CCR5-expressing control cells (Figure 2C;
Figures S3C and S3D). The cell surface binding constant (Kd)
of the G-3 aptamer was evaluated by flow cytometry. G-3
demonstrated good binding affinity to CCR5-expressing U373-
Magi-CCR5E and CEM-NKr-CCR5 cells (Figure 2D), with an
apparent Kd value of110 nM. In the CCR5-negative CEM cells,
only a very high concentration (>800 nM) of G-3 caused nonspe-
cific cellular binding (Kd > 3000 nM) (Figure 2D).
We next wanted to determine whether the selected G-3
aptamer requires CCR5 expression to target CCR5-expressing
cells. The specific knockdown of CCR5 using a previously vali-
dated CCR5 siRNA (Wheeler et al., 2011) demonstrated a loss
of CCR5 at both the mRNA and the cell surface (Figures S3E
and S3F). The suppression of CCR5 using siRNAs resulted in a
loss of the Cy3-labeled G-3 aptamer and control APC-labeled
CCR5 antibody (APC-CD195) binding to the CCR5-expressing
cells (Figure 2E; Figure S3G).
In addition, to examine whether or not the G-3 aptamer inter-
nalized in target cells, we carried out real-time live-cell z axis
confocal microscopy. The Cy3-labeled G-3 aptamer appeared
to be selectively internalized within the CCR5-expressing
U373-Magi-CCR5E cells, CEM-NKr-CCR5 cells, and primary
PBMCs, but not the U373-Magi and CEM control cells (Figures
2F and 2G), and appeared to be preferentially retained in the
cytoplasm (Figure 2H; Figure S3H).
CCR5 Aptamer Suppresses HIV-1 Infectivity of
R5-Tropic HIV-1 in Primary PBMCs and In Vivo
Generated Human CD4+ T Cells
HIV-1 commonly uses CCR5 or CXCR4 as coreceptors along
with CD4 to enter target cells (Berger et al., 1999). A number
of new experimental CCR5 receptor antagonists have been79–390, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 381
Table 2. Bioinformatics Analysis of HTS Data from Selection Rounds
Groups RNA 20-nt Random Sequence
Reads of Each Group
Round 5 Round 6 Round 7 Round 8 Round 9
1 G-1 AUCGUCUAUUAGUCGCUGGC 144,560 1,405,945 4,385,441 2,572,509 8,228,896
2 G-2 UCCUUGGCUUUUCGUCUGUG 447,271 2,700,796 5,191,611 4,572,814 3,151,265
3 G-3 GCCUUCGUUUGUUUCGUCCA 409,975 2,033,703 3,150,589 3,452,540 1,427,892
4 G-4 UCCCGGCUCGUUCGUCUGUG 129,752 695,110 1,564,701 2,568,638 1,148,903
5 G-5 UUCGUCAU UUUUCGUCUGGG 208,652 1,282,740 3,133,297 1,591,731 701,763
6 G-6 CCUUUCGUCUGUUUCUGCGC 69,760 158,855 233,840 159,454 94,378
Others orphan sequences 20,151 42,315 0 0 0
total reads of all groups 1,430,121 8,319,464 17,659,479 14,917,686 14,753,097
Bioinformatics analysis of RNA aptamers to identify related sequence and structure groups. After alignment of the top 40 sequences, six groups of RNA
aptamers were identified. The representative RNA aptamers and the reads of each group are listed here. Only the random sequences of the aptamer
core regions (50-30) are indicated.designed to interfere with the interaction between CCR5 and
HIV-1 (Signoret et al., 2000; Ugolini et al., 1999; Vila-Coro
et al., 2000). We therefore conducted a prophylactic HIV-1
experiment to determine whether the CCR5 aptamer would
also block HIV infectivity of R5 viruses in cell culture. In this
assay, primary PBMCs were first incubated with G-3 aptamer
for 4–6 hr followed by an infection with various HIV-1 stains
(R5 viruses: JR-FL and Bal; X4 viruses: IIIB and NL4-3). The
G-3 aptamer efficiently neutralized HIV-1 infectivity of R5 strains
with about 170–350 nM of IC50 (Table 3; Figures S4A and S4B).
Notably, the G3-aptamer had no observable suppression of
those cells infected with X4 strains (Figures S4C and S4D).
Furthermore, the capacity of CCR5 aptamers to inhibit HIV-1
replication was evaluated on in vivo generated human CD4+
T cells. We isolated mature human CD4+ T cells from humanized
mice. At sacrifice, splenocytes were harvested and human CD4+
T cells were collected by cell sorting. The cellular surface CCR5
expression was detected by flow cytometry analysis (Figures
S4E and S4F). The sorted CD4+ T cells were pretreated with
G-3 and subsequently were challenged ex vivo by R5 stains
(JR-FLorBal) or X4 strains (NL4-3), asdescribedabove.Similarly,
HIV-1JR-FLorBal replicationwas inhibited inhumanCD4+Tcells
from humanized mice (Figures S4G–S4I), which showed about
50–250 nM of IC50, as listed in Table 3. These data indicate that
the selected CCR5 aptamer (G-3) inhibits HIV-1 p24 production
and provided protection from HIV infection by R5 viruses.
Design of CCR5 Aptamer-siRNA Chimera Delivery
Systems that Can Bind to CCR5 and Are Internalized by
CCR5-Expressing Cells
We have previously delivered anti-HIV siRNAs specifically to
HIV-1-infected cells using RNA aptamer against HIV-1 envelop
gp120 protein (Zhou et al., 2009). In this study, we used a similar
strategy for cell-specific targeting of TNPO3 siRNA into cells ex-
pressing CCR5. TNPO3 (transportin 3) is a cellular factor that is
involved in facilitating cytoplasmic nuclear trafficking of the
HIV-1 preintegration complex and was previously shown by an
siRNA screen to block HIV-1 infection at the afferent stage (Brass
et al., 2008; Shah et al., 2013). As shown in Figures 3A and 3B,
two CCR5 aptamer-siRNA chimeras (G-3-TNPO3 OVH chimera
and G-3-TNPO3 Blunt chimera) were designed and prepared, as
previously described.382 Chemistry & Biology 22, 379–390, March 19, 2015 ª2015 ElsevieTo determine whether the designed chimeras are able to spe-
cifically bind and be internalized in CCR5-expressing cells, we
performed flow cytometry and a live-cell confocal microscopy
experiment. The G-3-TNPO3 OVH chimera was chosen for a
binding affinity test with PBMC-CD4+ cells, CEM-NKr-CCR5-
positive cells, and CEM-negative cells. The aptamer-sense
strand and antisense strand of the chimera were labeled by
Cy3 and Cy5 dye, respectively. Subsequently, sense and anti-
sense RNAs were annealed to form an aptamer-siRNA chimera
containing either single color or dual color labeling. Flow cyto-
metric results showed that G-3 (either nonlabeled or Cy3 labeled)
delivered Cy5-labeled siRNA to about 70%–80% of CCR5-
expressing PBMCs and CEM-NKr-CCR5 cells (Figures 3C–3E;
Figure S5). Similar with the parental G-3 aptamer, the Cy3-
labeled aptamer-siRNA chimeras selectively bound and were
internalized into cells expressing CCR5 after 5 hr post treatment
(Figure 3F).
CCR5 Aptamer-siRNA Chimeras Specifically
Knockdown TNPO3 Expression via the RNAi Pathway
and Do Not Trigger a Type I Interferon Response
To determine the functionality of the aptamer-delivered siRNAs,
after internalization, we evaluated the relative levels of inhibition
of TNPO3 expression. Specially, CEM-NKr-CCR5 cells or CEM-
NKr control cells were directly incubated with the aptamer-
siRNA chimeras, G-3 aptamer, or a nonfunctional control
aptamer-scrambled siRNA chimera. In parallel, cells were trans-
fected with the experimental RNAs by using a commercial trans-
fection agent (Trans IT-TKO). Silencing of TNPO3 was assessed
by the degree of TNPO3mRNA knockdown using qRT-PCR (Fig-
ure 4A). In the presence of a transfection agent, TNPO3 gene
silencing was observed in both CEM-NKr-CCR5 and CEM-NKr
control cells after the treatment of G-3-TNPO3 chimeras. How-
ever, in the absence of a transfection agent, the G-3-TNPO3
chimeras, but not the G-3-scrambled siRNA chimera or nontar-
geting aptamer-TNPO3 siRNA conjugate (gp120 aptamer
A-1-stick-TNPO3), reduced TNPO3 mRNA levels. Importantly,
the reduction was specific to CCR5-positive cells, as control
CEM-NKr-negative cells treated with either of the G-3-TNPO3
chimeras exhibited no TNPO3 mRNA reduction (Figure 4A).
Similarly, the G-3 aptamer-delivered TNPOs DsiRNA also re-
sulted in a decrease in target mRNA levels 48 hr post treatmentr Ltd All rights reserved
Figure 2. Cell-Type-Specific Binding and Internalization Studies of Individual RNA Aptamers
(A) Cell-type-specific binding/internalization of the individual aptamer was evaluated by qRT-PCR. The 0-RNA pool was used as a negative control. Data
represent the average of three replicates. Cell surface binding of Cy3-labeled RNAs was assessed by flow cytometry.
(B) Cy3-labeled RNAs were tested for binding to U373-Magi-CCR5-positive cells and U373-Magi-negative cells. APC-CD195 antibody was used to stain cellular
surface CCR5.
(C) The G-3 aptamer was chosen for a further binding affinity test with PBMC-CD4+ cells, CEM-NKr-CCR5-positive cells, and CEM-negative cells.
(D) Cell surface binding constant (Kd) of G-3 was evaluated by flow cytometry.
(E) Knockdown of CCR5 reduced binding affinity of aptamers. A scrambled siRNA (NC1) was used as a negative control. Asterisks indicate a significant difference
compared with control (p < 0.01, Student’s t test). Data represent the average of three replicates. Internalization analysis.
(F) U373-Magi-CCR5-positive cells, U373-Magi-negative cells, CEM-NKr-CCR5-positive cells, CEM-negative cells, or (G) PBMC-CD4+ cells were grown in
35-mm plates treated with polylysine and incubated with a 67-nM concentration of Cy3-labeled G-3 aptamer in complete culture media for real-time live cell
confocal microscopy analysis. The images were collected using 403 magnification.
(H) Localization analysis.
Error bars represent SD.in human PBMC-CD4+ cells, with efficiency comparable with a
previous validated transfection agent (G5 dendrimer) (Zhou
et al., 2011) (Figure 4B).Chemistry & Biology 22, 3In order to determine whether the siRNAs released from the
chimeras were actually triggering RNAi, we next investigated
siRNA-directedmRNAcleavage using amodified 50-RACE (rapid79–390, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 383
Table 3. The IC50 Value Was Calculated Based on the HIV-1 Protection Assay
Virus
Day 3 Post Treatment Day 5 Post Treatment Day 7 Post Treatment
R2IC50 (nM)
Primary PBMCs (G-3 aptamer) R5 JR-FL 219.7 ± 55.6 232.6 ± 38.3 170.4 ± 47.0 >0.9
R5 Bal 349.4 ± 77.2 354.3 ± 113.3 >1,000 >0.9
X4 IIIB >1,000 not converged not converged <0.2
X4 NL4-3 not converged not converged not converged <0.5
Primary PBMCs (G-3-TNPO3 OVH
Chimera)
R5 JR-FL 23.2 ± 6.2 142.6 ± 41.3 79.3 ± 21.6 >0.9
In vivo generated human CD4+ T cells
(G-3 aptamer)
R5 JR-FL 48.0 ± 8.6 58.5 ± 11.2 17.1 ± 5.9 >0.9
R5 Bal 147.6 ± 45.7 245.5 ± 35.8 243.2 ± 46.2 >0.9
X4 NL4-3 not converged not converged not converged –
Human PBMC-CD4+ cells or in vivo generated human CD4+ T cells were pretreated with experimental RNAs before exposure to HIV-1 viruses.amplification of cDNA ends) PCR assay. It has been established
that Ago2 mediates cleavage between bases 10 and 11 relative
to the 50 end of each siRNA (Matranga et al., 2005). Thus, the
RACE PCR product sequence analyses of the target should
reveal a 30 linker addition at the base positioned 11 nucleotides
from the 50 end of the siRNA guide strand. PCR bands of the
predicted lengths were detected in the total RNAs from
CEM-NKr-CCR5 cells treated with the chimeras after two
nested PCR reactions (Figure 4C). The individual clones were
sequenced to verify the expected PCR products. Several cleav-
age sites were found in the samples treated with the two
chimeras. Figure 4D indicates the Ago2 cleavage sites and
proposed direction of Dicing. For the OVH chimera, one major
cleavage was observed, suggesting that Dicer preferentially
entered the DsiRNA from the 30-overhang of the sense
strand. The short linker (2 U) may limit the Dicer entry from
the 50-end of the sense strand. In the case of the Blunt
chimera, several different cleavage sites were generated,
suggesting that Dicer might bidirectionally enter the DsiRNA
to generate different 21-mer siRNA species. Different from
the observation in the OVH chimeras, the longer linker (8 U)
of the Blunt chimera may allow the Dicer entry from the 50-end
of the sense strand. These results provide strong evidence
that the chimera-delivered siRNAs are processed intracellularly
and trigger sequence-specific degradation of the TNPO3 target
mRNA.
As a final test for nonspecific inhibitory activity, the aptamer-
mediated siRNA delivery system was monitored for induction
of type I interferon (IFN) response. The levels of two different
type I IFN-stimulated gene expressions (mRNAs) were quantified
by qRT-PCR (Figure 4E). We used IFN-a as a positive control to
confirm upregulation of p56 (CDKL2, cyclin-dependent kinase-
like 2) and OAS1 (20-50-oligoadenylate synthetase 1) gene
expression. Our results indicated that the treatment of PBMC-
CD4+ cells with these chimeras did not activate the type I IFN
pathway.
CCR5 Aptamer-siRNA Chimeras Inhibit HIV-1 Infection
in Primary Human PBMCs
It has been reported previously that as one of the HIV-1 host de-
pendency factors (HDFs), TNPO3 is a karyopherin required for
viral integration, suggesting it is a potential therapeutic target.
Therefore, we conducted two different experiments to assess384 Chemistry & Biology 22, 379–390, March 19, 2015 ª2015 Elseviethe anti-HIV-1 activities of the CCR5 aptamer-mediated
TNPO3 siRNA delivery system.
The first assay is a prophylactic HIV-1 experiment, performed
as described above. The experimental RNAs were incubated
with human PBMC-CD4+ cells. After 4–6 hr treatment, the cells
were challenged by the R5 virus (HIV-1 JR-FL). The culture
supernatants were collected at 5 days after treatment for HIV-1
p24 antigen ELISA. Results presented in Figure 5A showed
that both of the aptamers and chimera inhibited p24 production,
but the strongest inhibition was observed with the G-3-TNPO3
OVH chimera treatment, which showed a lower IC50 value
(Table 3). To confirm that the siRNA component was functioning
along with the aptamer, following internalization of the chimera in
infected cells, we also evaluated the relative levels of inhibition of
TNPO3 gene expression by qRT-PCR assay (Figure 5B). Specific
downregulation of the TNPO3 mRNA was observed, a direct
consequence of the CCR5 aptamer-mediated DsiRNA delivery.
In contrast, treatment of these cells with the CCR5 aptamer
alone or unrelated RNA had no effect on TNPO3 levels.
In the second experiment, human PBMC-CD4+ cells were in-
fected with JR-FL virus for 5 days and then incubated with
CCR5 aptamer and aptamer-siRNA chimeras. At different days
post treatment, aliquots of the media were assayed for viral
p24 antigen levels. An anti-gp120 aptamer (A-1-stick) was
used here as a positive control. The results of these analyses
(Figure 5C; Figure S6) indicated that both CCR5 aptamer and
aptamer-siRNA chimera were also able to suppress HIV-1 repli-
cation at day 3 and day 5 post treatment in which cells were in-
fected with HIV-1 virus prior to the treatment. Although the
gp120 aptamer showed a better inhibition than the CCR5 ap-
tamer, the strongest and most prolonged suppression was
observed with G-3-TNPO3OVH chimera treatment. Collectively,
these results provide further evidence that the aptamer-deliv-
ered siRNA triggers RNAi, thereby resulting in dual inhibitory
effect on HIV-1 replication.
DISCUSSION
The concept of nucleic acid-based therapy (ribozyme, decoy,
antisense oligonucleotide, mRNA, aptamer, siRNA, microRNA)
has been extensively exploited for the treatment of various hu-
man diseases (Stull and Szoka, 1995). Although they each could
be used as a stand-alone inhibitor, the combinatorial use ofr Ltd All rights reserved
Figure 3. The Design and Binding Affinity of Aptamer-siRNA Chimeras
(A and B) Schematic of CCR5 aptamer-siRNA chimeras. The region of the aptamer is responsible for binding to CCR5, and the siRNA is targeting TNPO3 gene.
A linker (2 or 8 U) between the aptamer and siRNA is indicated in green. Two versions, G-3-TNPO3 OVH chimera (A) and G-3-TNPO3 Blunt chimera (B), were
designed.
(C–E) Cell surface binding of fluorescent dye-labeled RNAswas assessed by flow cytometry. The Cy3-labeled 0-RNA pool and Cy5-labeled siRNAwere used as a
negative control. The G-3-TNPO3OVH chimera was chosen for a binding affinity test with (C) PBMC-CD4+ cells, (D) CEM-NKr-CCR5-positive cells, and (E) CEM-
negative cells. The aptamer-sense strand and antisense strand of the chimera were labeled by Cy3 and Cy5 dye, respectively. They were then annealed to form
the aptamer-siRNA chimera.
(F) Internalization analysis. The images were collected using 403 magnification, as described previously.various nucleic acids has shownmore potential and advantages,
including synergistic, prolonged suppression, and especially,
targeted therapy when a cell-type-specific nucleic acid aptamer
was adopted (Thiel and Giangrande, 2009). In previous studies,
investigators have demonstrated that HIV-1 genome and host
genes can be targeted in combination with various antiviral nu-
cleic acids (ribozyme, siRNA, decoy, etc.) in a tailored manner,
thereby providing more efficacies in blocking viral replication
and preventing the emergence of resistant variants (ShumChemistry & Biology 22, 3et al., 2013; Zhou and Rossi, 2011a). By functionalizing the
cell-specific aptamers with therapeutic agents, the cellular up-
take is enhanced, thereby improving the therapeutic efficacy.
We have also capitalized on the exquisite specificity of an anti-
gp120 aptamer to delivery anti-HIV siRNAs into HIV-infected
cells, with the net result that the replication and spread of HIV
is strongly inhibited by the combined action of the aptamer
and the siRNAs against HIV-1 tat/rev or HDFs. In this case, the
aptamers can function as both targeted delivery reagents and79–390, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 385
Figure 4. CCR5 Aptamer-Delivered siRNAs Specifically Knockdown TNPO3 Expression via the RNAi Pathway
(A and B) Relative TNPO3 mRNA expression was detected by real-time PCR in (A) CEM-NKr-CCR5 and CEM-NKr-negative cells, and (B) human PBMC-CD4+
cells. Unrelated aptamer-siRNA chimera (gp120 aptamer A-1 or mutant CD4 aptamer) and G-3 aptamer-scrambled siRNA chimera were used as negative
controls. Asterisks indicate a significant difference comparedwith control (p < 0.01, Student’s t test). 50-RACE PCR analysis of TNPO3DsiRNA delivered byCCR5
aptamer-siRNA chimeras.
(legend continued on next page)
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Figure 5. Dual Inhibition on HIV-1 Infection
Mediated by Aptamer-Based siRNA Deliv-
ery System
(A) HIV-1 protection assay. Human PBMC-CD4+
cells were pretreated with experimental RNAs and
then infected with JR-FL virus.
(B) The siRNA delivered by aptamers knocked
down TNPO3 gene expression in human PBMCs.
Relative TNPO3 mRNA expression was detected
by real-time PCR, with GAPDH as internal control.
Asterisks indicate a significant difference com-
pared with control (p < 0.01, Student’s t test).
(C) HIV-1 challenge assay. Human PBMC-CD4+
cells were infected with JR-FL and then incubated
with experimental RNAs. A gp120 aptamer (A-1-
stick) and an unrelated aptamer (R-1-stick) were
used as positive and negative controls, respec-
tively. Data represent the average of triplicate
measurements of p24.
Error bars represent SD.antiviral agents. In the present study, we wish to generate anti-
CCR5 RNA aptamers capable of specifically targeting HIV-1-
susceptible cells (as a therapeutic siRNA delivery agent) and
inhibiting HIV-1 infectivity (as antiviral agent) via block of the
CCR5 required for HIV-1 to enter cells.
Considering the limited resource and the risk of changed
conformation of purified CCR5 membrane protein after purifica-
tion, we therefore used live-cell-based SELEX methodology for
generating cell-type-specific RNA aptamers. HTS technology
and bioinformatics analysis were also combined here to facilitate
the rapid identification of individual RNA aptamers and show
the library evolution. We obtained and processed millions of
sequence reads from each round, which provide comprehensive
and in-depth information, such as the basic sequences, total
reads, the complexity of the library, the enrichment factor, fre-
quency of each unique sequences, and distribution of each
nucleotide at random region, thereby helping us to better under-(C) Nested PCR products were resolved in an agarose gel and specific siRNA-mediated RACE PCR cleavag
(D) The positions of the siRNA-directed cleavage sites in the TNPO3 target RNA are indicated with a pair of g
predicated siRNA species are also shown with blue and red arrows. The proposed directions of Dicer entry
(E) IFN gene activation assays in human PBMCs. The IFN response genes encoding p56 (CDKL2) andOAS1 w
the average of three replicate measurements.
Error bars represent SD.
Chemistry & Biology 22, 379–390, March 19, 2015stand the selection progression and the
molecular evolution. In comparison, the
conventional approach for aptamer iden-
tification, in which the final SELEX library
is generally cloned into a plasmid vector
and dozens to a few hundred individual
clones are picked up for sequencing
analysis, cannot provide such thorough
insight into the selection progression
and aptamer evolution. Our HTS analysis
revealed that maximal molecular enrich-
ment was reached at the seventh or the
eighth selection round, which suggested
a stop time point. Subsequently, addi-
tional selection rounds did not furtherimprove the enrichment, implying that an increase of onemoder-
ate sequence probably occupied the proportion of some better
aptamers. Furthermore, the evolution of a particular sequence
or group revealed that some aptamer candidates have already
been identified by HTS at a much earlier selection round (e.g.,
the fifth or sixth round), which cannot be done by traditional clon-
ing and sequencing approach, due to their limited sequences.
The use of the minimum number of selection cycles is able to
significantly improve the SELEX efficiency and the aptamer effi-
cacy. We demonstrate the power of HTS technique and bioinfor-
matics analysis in the rapid identification of aptamers.
HIV replicates primarily in T lymphocytes and cells of the
macrophage lineage. CD4 is required for virus binding to the
cell surface, and coreceptors (CCR5, CXCR4) are required for
viral fusion with the cell membrane (Berger et al., 1999; Murphy
et al., 2000; Pelchen-Matthews et al., 1999). M-tropic HIV-1
stains (R5 viruses) use CCR5 for the coreceptor, and T-tropice mRNA products are marked by a bold arrow.
ray triangles. According to mRNA cleavage, these
are indicated by a bold black arrow.
ere measured by qRT-PCR. These data represent
ª2015 Elsevier Ltd All rights reserved 387
strains (X4 viruses) use CXCR4. Successes in discovering new
classes of CCR5 inhibitors targeted to the step of HIV-1 entry
have been reported in recent years. Previous studies have
demonstrated that the chemokine RANTES (regulated on activa-
tion, normal T cell expressed and secreted), a natural CCR5
ligand, and an NH2-terminal modified form of RANTES (AOP-
RANTES) protect cells from HIV infection by R5 viruses (Sabbe
et al., 2001; Signoret et al., 2000). This inhibition of virus infection
may be explained by either occupancy of CCR5 and blocking of
interaction with the CD4-gp120 complex, or receptor sequestra-
tion following internalization (Mack et al., 1998; Mariani et al.,
1999; Vila-Coro et al., 1999). Therefore, we designed a prophy-
lactic HIV-1 experiment to determine whether or not CCR5
aptamer can specifically suppress R5-tropic virus infection.
Our results indicated that the G-3 aptamer specifically neutral-
ized R5 virus infection in primary PBMCs and in vivo generated
human CD4+ T cells with a nanomolar IC50 value, but no obvious
antiviral effect was observed in X4 virus-infected cells, thereby
suggesting a HIV-1 tropic-selective inhibition. Therefore, CCR5
aptamers show potential as a therapeutic by itself for HIV-1
infection.
In the present study, we used TNPO3 siRNA as proof of prin-
ciple to show successful delivery as well as specific mRNA
cleavage. Through dual color flow cytometry assay, we found
that at least 80% siRNA could be delivered by the CCR5 aptamer
into various CCR5 expression cells. We also observed that the
aptamer or aptamer-siRNA chimeras were mainly located within
the cytoplasm by real-time confocal microscopy, suggesting
that the CCR5 aptamer may be internalized probably by CCR5
receptor-mediated endocytosis. In addition, we conducted
both a prophylactic HIV-1 experiment and an HIV-1 challenge
experiment to access the anti-HIV-1 activity of the chimera.
When the CCR5 aptamer-siRNA chimera was applied on human
PBMCs either before exposure to the virus or after HIV-1 infec-
tion, it resulted in stronger and prolonged suppression on
HIV-1 replication in comparison with the CCR5 aptamer alone.
This is likely due to the contribution of the siRNA component of
the chimera in silencing TNPO3 expression in the treated cells.
Several major challenges still remain that hinder the rapid tran-
sition of aptamer-mediated technology from the research labo-
ratory to the clinic. As single-stranded nucleic acid molecules,
aptamers are subject to nuclease-mediated degradation and
rapid renal filtration/clearance. The lower or moderate affinities
of aptamers often compromise the therapeutic efficacy. Proper
modifications of aptamers can help to improve their pharmaco-
kinetics. For example, aptamers have been conjugated to poly-
ethylene glycol to increase their bioavailability and circulating
half-life in vivo. Incorporating protective functional groups (e.g.,
thiol-phosphate, 20-fluoro, 20-amino, etc.) in the phosphate
backbone or 20-position of the ribose sugar can improve their
nuclease resistance, and even their binding affinity. In addition,
multiple aptamers and therapeutic agents can be combined to
various nanocarrier systems, probably further enhancing binding
affinity of the aptamer and loading capacity of the drug, eventu-
ally improving therapeutic index.
In summary, we have demonstrated that the combinatorial use
of live-cell-based SELEX with HTS and bioinformatics analysis
not only represents a powerful and rapid method for generating
cell-type-specific, internalizing aptamers that are able to recog-388 Chemistry & Biology 22, 379–390, March 19, 2015 ª2015 Elsevienize a particular target membrane protein under native condition
but also provides comprehensive information that could help us
to better understand selection progression and improve evolu-
tion efficiency. In addition, the CCR5 aptamer-based siRNA de-
livery system serves as dual functional inhibitors and therefore
provides better efficacy than either the aptamer or siRNA applied
alone. Therefore, the cell-specific, internalizing CCR5 aptamer-
functionalized agents may offer great promise for cell-type- or
tissue-specific delivery of various therapeutic drugs for targeted
HIV-1 therapy. Notably, these targeted delivery approaches can
be used in disease models beyond HIV-1, such as cancer.
SIGNIFICANCE
Although there is currently no cure for HIV/AIDS, a variety of
antiretroviral drugs that act on different stages of the HIV life
cycle can be used in combination to control the virus. Highly
active antiretroviral treatment (HAART) has proved to be the
standard approach for delaying the progression to AIDS and
reducing the risk of death and disease complication. How-
ever, severe side effects, compliance problems, and drug
resistances complicate the use of this therapy. Nucleic
acid-based therapeutics have been actively developed as
alternative or adjuvant agents for those chemical antiviral
drugs in order to surmount those drawbacks.
RNAi-based therapeutics have unique therapeutic poten-
tial for the treatment of HIV-1 infection, since the entire
genome of the virus is target. Another type of nucleic acid
(aptamers) shows promise as a potent class of anti-HIV
agent and can in addition function as a cell-type-specific
delivery vehicle for targeted RNAi. We reasoned that a
combinatorial use of various antiviral nucleic acids such as
siRNAs and aptamers could be more efficacious in blocking
viral replication and preventing the emergence of resistant
variants.
CCR5 is a seven-pass transmembrane receptor expressed
by T cells and macrophages that serves as a coreceptor for
macrophage-tropic HIV-1. Loss of CCR5 is associated with
resistance to HIV-1. We therefore generated CCR5 RNA ap-
tamers capable of specifically targeting HIV-1-susceptible
cells (as an siRNA delivery agent) and inhibiting HIV-1 infec-
tivity (as an antiviral agent) via block of the CCR5 required
for HIV-1 to enter cells. The importance of such a strategy
for the treatment of HIV-1 cannot be overstated, as viral var-
iants resistant to current therapies are on the rise in devel-
oped nations and portend a new pandemic of resistant virus.
Notably, these delivery approaches can be used in disease
models beyond HIV-1, such as cancer.
EXPERIMENTAL PROCEDURES
Live-Cell-Based SELEX
The starting DNA library contained 20 nt of random sequences and was syn-
thesized by Integrated DNA Technologies (Coralville). The random region is
flanked by constant regions, which include the T7 promoter (underlined) for
in vitro transcription and a 30-tag for RT-PCR. The 51-mer single-stranded
DNA oligo library for the RNA library is 50-GGG AGG ACG ATG CGG-N20-
CAG ACG ACT CGC CCG A-30 (51 nt). The 50 and 30constant sequences are
50-TAA TAC GAC TCA CTA TAG GGA GGA CGA TGC GG-30 (32 mer) and
50-TCG GGC GAG TCG TCT G-30 (16 mer), respectively. The DNA randomr Ltd All rights reserved
library (0.4 mM) was amplified by PCR using 3 mM each of 50- and 30-primers,
along with 2mMMgCl2 and 200 mMof each dNTP. To preserve the abundance
of the original DNA library, PCR was limited to ten cycles. The PCR amplifica-
tion protocol is as follows: 93C for 3 min, followed by ten cycles of heating to
93C for 1 min, 63C for 1 min, and 72C 1min. A final extension step was per-
formed for 7 min at 72C. After the PCR reactions (ten reactions, 100 ml per re-
action), the amplified double-strandedDNA (dsDNA) pool was recovered using
a QIAquick Gel purification kit. The resulting dsDNA was converted to an RNA
library using the DuraScription Kit (Epicentre), according to the manufacturer’s
instructions. In the transcription reaction mixture, CTP and UTP were replaced
with 20-F-CTP and 20-F-UTP to produce ribonuclease-resistant RNA. The reac-
tions were incubated at 37C for 6 hr, and subsequently the template DNAwas
removed by DNase I digestion. The transcribed RNA pool was purified in an
8% polyacrylamide/7 M urea gel. The purified RNA library was quantified by
UV spectrophotometry.
SELEX was performed principally as described by Tuerk and Gold (1990),
and here we applied a modified cell-based SELEX described by Thiel et al.
(Cerchia et al., 2005, 2009a; Thiel et al., 2012a, 2012b). Generally, in each
round, the desired amount of RNA pools was refolded in 3 ml of refolding
buffer, heated to 65C for 5 min, and then slowly cooled to 37C. Incubation
was continued at 37C for 10 min. The refolding or washing buffer contained
DPBS (pH 7.0–7.4) and Ca2+ and Mg2+, 1 mM CaCl2, 2.7 mM KCl, 1.47 mM
KH2PO4, 1 mMMgCl2, 136.9 mMNaCl, 2.13 mMNa2HPO4. The binding buffer
used during the selection was prepared by adding yeast tRNA to washing
buffer to reduce nonspecific binding. To avoid nonspecific interaction between
nucleic acids and the cell surface, the tRNA (100 mg/ml) as a competitor was
first incubated with nontargeted cells or targeted cells at 37C for 25 min
and was then ready for the selection step. The counterselection step was per-
formed per cycle to minimize nonspecific binding with the nontargeted cells.
Subsequently, the unbound RNA pool was transferred to the targeted cells
for positive selection.
For the first cycle of selection, 24 hr before selection, U373-Magi cells
(CCR5 negative) and U373-Magi-CCR5E cells (CCR5 positive) were seeded
at equal density (5 3 106 cells per plate) on a 150 mm tissue culture dish
with 25 ml of complete culture medium. On the day of selection, U373-Magi-
negative cells were washed three times with 15 ml of prewarmed washing
buffer to remove dead cells and then 15 ml of prewarmed binding buffer
was added supplementedwith 100 mg/ml yeast tRNAs. After 25min incubation
at 37C, the buffer was removed and the refolded RNA pool (4 nmol 0-RNA
pool in 15 ml of refolding buffer) was added to the U373-Magi-negative cells
for 30min at 37C. The precleared 0-RNA pool (supernatants with unbound se-
quences from the negative cell plate) was ready for positive selection. Mean-
while, as described above, U373-Magi CCR5-positive cells were also washed
and incubated with 15 ml of prewarmed binding buffer supplemented with
100 mg/ml yeast tRNAs. After 25 min incubation at 37C, the buffer was
removed and the precleared 0-RNA pool was subsequently transferred to
the U373-Magi CCR5-positive cells for 30 min at 37C. Following incubation
of the preclean RNA pool, the U373-Magi CCR5-positive cells were washed
twice with 12 ml of prewarmed washing buffer to remove unbound sequences
and cell surface RNAs with weak binding. Cell surface bound RNA with strong
binding affinity and internalized RNA sequences were recovered by TRIzol
(Invitrogen) extraction by following the manufacturer’s instructions.
The recovered RNA pool was reverse transcribed using the ThermoScript
RT-PCR system (Invitrogen) and amplified for 15 cycles of PCR. The PCR
amplification protocol was as follows: 95C for 5 min, followed by 15 cycles
of heating to 95C for 1 min, 63C for 1 min, and 72C for 1 min. A final exten-
sion step was performed for 7min at 72C. After the amplified dsDNA template
was purified using a QIAquick Gel purification kit, it was transcribed to a new
RNA pool as described above for the next round of selection. With SELEX
progress, the number, density, volume, RNA amount, washing times, tRNA
competitor amount, and incubation time of the cells were progressively
adjusted in order to increase the pressure of aptamer selection. The selection
conditions are summarized in Table S1.
Inhibit HIV-1 Replication in Human PBMCs
Assay 1: HIV-1 Protection Assay
HIV-1 protection assay was performed in 24-well tissue culture plates. PBMCs
were washed once with prewarmed PBS, and 43 105 PBMCs were seeded toChemistry & Biology 22, 3each well of the assay plates. Subsequently, experimental RNAs (800 nM final
concentration) were added. Plates were incubated for 4–6 hr at 37C in a hu-
midified 5% CO2 incubator. HIV-1 R5 strains (JR-FL, MOI = 0.01) were added
into each well. After 24 hr incubation, the cells were gently washed with pre-
warmed PBS to eliminate free viruses and were incubated sequentially at
37C in a humidified 5% CO2 incubator. The culture supernatants were
collected at different time points after infection (3, 5, and 7 days). The HIV-1
p24 antigen analyses were performed using a Coulter HIV-1 p24 antigen assay
(Beckman Coulter), in accordance with the manufacturer’s instructions. The
total RNA was isolated for qRT-PCR analysis.
Assay 2: HIV-1 Challenge Assay
Experimental RNAs were prepared and refolded in refolding buffer. Human
PBMCs were infected with HIV-1 JR-FL virus for 5 days (MOI = 0.01). Prior
to RNA treatment, the infected cells were gently washed with PBS three times
to remove free virus. Next, 1 3 105 infected cells and 1 3 105 uninfected cells
were incubated with experimental RNAs at 800 nM final concentration in
24-well plates at 37C. The culture supernatants were collected at different
times (3, 5, and 7 days). The p24 antigen analyses were performed as
described above.
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